GW Pharmaceuticals PLC (NASDAQ:GWPH) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

GWPH has been the subject of several other research reports. Zacks Investment Research downgraded GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. ValuEngine upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Maxim Group set a $135.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Monday, August 7th. Cantor Fitzgerald reiterated a “buy” rating and issued a $208.00 price objective on shares of GW Pharmaceuticals PLC in a research report on Tuesday, May 9th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $160.00 price objective (down previously from $162.00) on shares of GW Pharmaceuticals PLC in a research report on Thursday. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $147.94.

GW Pharmaceuticals PLC (GWPH) traded down 0.48% on Thursday, reaching $101.75. 218,738 shares of the company’s stock traded hands. GW Pharmaceuticals PLC has a 12 month low of $79.62 and a 12 month high of $137.88. The firm’s 50-day moving average is $107.48 and its 200 day moving average is $113.40. The firm’s market cap is $2.58 billion.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by $0.34. The firm had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $2.10 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. During the same period in the prior year, the company earned ($0.05) EPS. Equities analysts predict that GW Pharmaceuticals PLC will post ($5.28) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/13/gw-pharmaceuticals-plc-gwph-rating-lowered-to-hold-at-bidaskclub.html.

Several institutional investors have recently made changes to their positions in GWPH. Creative Planning increased its position in shares of GW Pharmaceuticals PLC by 1.4% in the second quarter. Creative Planning now owns 2,532 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 35 shares in the last quarter. Advisor Group Inc. increased its position in shares of GW Pharmaceuticals PLC by 10.7% in the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 145 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of GW Pharmaceuticals PLC by 8.5% in the second quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 162 shares in the last quarter. HighTower Advisors LLC increased its position in shares of GW Pharmaceuticals PLC by 10.3% in the first quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 191 shares in the last quarter. Finally, Rothschild Investment Corp IL increased its position in shares of GW Pharmaceuticals PLC by 2.7% in the first quarter. Rothschild Investment Corp IL now owns 10,437 shares of the biopharmaceutical company’s stock worth $1,262,000 after buying an additional 272 shares in the last quarter. Institutional investors own 75.77% of the company’s stock.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.